Awardee OrganizationMASSACHUSETTS GENERAL HOSPITAL
Description
Abstract Text
Induction of lymphohematopoietic chimerism through bone marrow
transplantation (BMT) can lead to life-long transplantation tolerance
without the need for chronic immunosuppression. However, BMT across
major histocompatibility (MHC) barriers is severely limited by problems
associated with the severity of the host preparative regimen required,
the potential for lethal graft-versus-host disease (GVHD), and
engraftment failure. These problems could potentially be avoided by
using a gene therapy approach to introduce allogeneic MHC genes into
autologous bone marrow rather than transferring immunocompetent cells
into the host. Using retroviral gene therapy, the allogeneic MHC class
I gene H-2Kb (Kb) has been introduced into syngeneic bone marrow.
Reconstitution of lethally irradiated syngeneic mice with bone marrow
transduced with the Kb gene has been found to produce the specific
prolongation of Kb bearing skin allograft survival. The major goals of
this proposal are to examine the mechanism(s) by which expression of the
transduced allogeneic MHC gene in BM derived cells lead to prolonged
survival of Kb disparate skin grafts, and to establish conditions
permitting long-term expression of the transduced gene in BM derived
cells for the purpose of inducing life-long allograft acceptance. The
specific aims are to: 1) Establish conditions permitting long-term
expression of the retrovirally transduced H-2Kb gene in bone marrow
derived cells; 2) Determine the mechanism by which expression of the
transduced MHC class I gene product affects reactivity of anti-Kb CD8
T cells. 3) Determine the mechanism by which expression of retrovirally
transduced Kb in bone marrow derived cells affects the ability of CD4
T cells to respond Kb disparate targets; and, 4) Evaluate the ability
of Kb expressing cells of various lineages to induce specific
prolongation of Kb disparate skin graft survival. These studies should
provide practical information important for the field of transplantation
on the mechanism of tolerance induced by gene therapy, and should also
provide theoretical insights which may advance our understanding of
self-nonself discrimination with respect to MHC antigens.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
MHC class I antigenMHC class II antigenRetroviridaeT cell receptorbone marrowcell mediated lymphocytolysis testcell typecytotoxic T lymphocyteflow cytometrygene expressiongene therapygenetic manipulationgenetic transductiongenetically modified animalshelper T lymphocytehomologous transplantationlaboratory mousemajor histocompatibility complexmutantpolymerase chain reactionskin transplantationsuppressor T lymphocytetissue /cell culturetransplant rejectiontransplantation immunology
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
073130411
UEI
FLJ7DQKLL226
Project Start Date
01-June-1998
Project End Date
30-April-2003
Budget Start Date
01-May-2000
Budget End Date
30-April-2001
Project Funding Information for 2000
Total Funding
$261,786
Direct Costs
$163,467
Indirect Costs
$98,319
Year
Funding IC
FY Total Cost by IC
2000
National Institute of Allergy and Infectious Diseases
$261,786
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI043619-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI043619-03
Patents
No Patents information available for 5R01AI043619-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI043619-03
Clinical Studies
No Clinical Studies information available for 5R01AI043619-03
News and More
Related News Releases
No news release information available for 5R01AI043619-03
History
No Historical information available for 5R01AI043619-03
Similar Projects
No Similar Projects information available for 5R01AI043619-03